scispace - formally typeset
D

Dong Wan Kim

Researcher at Seoul National University Hospital

Publications -  880
Citations -  61091

Dong Wan Kim is an academic researcher from Seoul National University Hospital. The author has contributed to research in topics: Lung cancer & Crizotinib. The author has an hindex of 89, co-authored 833 publications receiving 49632 citations. Previous affiliations of Dong Wan Kim include University of California, Irvine & Korea University.

Papers
More filters
Journal ArticleDOI

Electrospun-Cellulose derived Free-standing Carbon Nanofibers as Lightweight, Ultrathin, and Stackable Interlayers for Lithium-Sulfur Batteries

Dongjoo Park, +2 more
- 01 Feb 2021 - 
TL;DR: In this paper, a free-standing carbon nanofibers based on electrospun-cellulose (ACCF) was used as a lightweight interlayer for lithium-sulfur batteries.
Journal ArticleDOI

Geriatric Nutritional Risk Index as a prognostic marker in patients with extensive-stage disease small cell lung cancer: Results from a randomized controlled trial

Gyeong Won Lee, +9 more
- 01 Jan 2020 - 
TL;DR: The clinical impact of the Geriatric Nutritional Risk Index in patients with extensive‐stage disease small cell lung cancer (ED‐SCLC) have not previously been reported.
Journal ArticleDOI

Synthesis of manganese oxide nanostructures using bacterial soft templates

Hyun Woo Shim, +3 more
- 24 Oct 2011 - 
TL;DR: In this paper, a Bacillus subtilis-directed synthesis of manganese oxides with rod-and hollow-type nanostructures via bacterial templates was performed.
Journal ArticleDOI

Phase II clinical trial of SKI-2053R, a new platinum analog, in the treatment of patients with advanced gastric adenocarcinoma

Noe Kyeong Kim, +9 more
- 01 Oct 1999 - 
TL;DR: This study evaluated the efficacy and toxicity of SKI‐2053R in the treatment of patients with advanced gastric adenocarcinoma and suggested it is less nephrotoxic than cisplatin.
Journal ArticleDOI

EGFR mutations as a predictive marker of cytotoxic chemotherapy

Jin Hyun Park, +12 more
- 01 Aug 2012 - 
TL;DR: It is indicated that lung cancer patients with EGFR-mutations had longer PFS with taxane than gemcitabine when receiving a platinum-based doublet regimen, and the predictive meaning of EGFR mutations for cytotoxic chemotherapy should be further investigated.